Insulet (PODD) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Insulet (NASDAQ: PODD):

  • 8/6/2019 – Insulet had its price target raised by analysts at Guggenheim from $100.00 to $145.00. They now have a “positive” rating on the stock.
  • 8/6/2019 – Insulet was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $155.00 price target on the stock, up previously from $120.00.
  • 8/6/2019 – Insulet had its price target raised by analysts at Piper Jaffray Companies from $130.00 to $160.00. They now have an “overweight” rating on the stock.
  • 8/6/2019 – Insulet had its price target raised by analysts at BMO Capital Markets from $130.00 to $150.00. They now have an “outperform” rating on the stock.
  • 8/6/2019 – Insulet had its price target raised by analysts at Raymond James from $125.00 to $135.00. They now have an “outperform” rating on the stock.
  • 8/6/2019 – Insulet had its price target raised by analysts at Morgan Stanley from $127.00 to $135.00. They now have an “equal weight” rating on the stock.
  • 8/6/2019 – Insulet had its price target raised by analysts at BTIG Research to $140.00. They now have a “buy” rating on the stock.
  • 8/6/2019 – Insulet had its price target raised by analysts at Jefferies Financial Group Inc from $105.00 to $140.00. They now have a “buy” rating on the stock.
  • 8/6/2019 – Insulet had its price target raised by analysts at Canaccord Genuity from $110.00 to $135.00. They now have a “buy” rating on the stock.
  • 8/1/2019 – Insulet was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 7/16/2019 – Insulet had its price target raised by analysts at Morgan Stanley from $98.00 to $127.00. They now have an “equal weight” rating on the stock.
  • 7/13/2019 – Insulet was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/10/2019 – Insulet had its “outperform” rating reaffirmed by analysts at Svb Leerink Llc.
  • 6/28/2019 – Insulet had its price target raised by analysts at Piper Jaffray Companies from $110.00 to $130.00. They now have a “positive” rating on the stock.
  • 6/27/2019 – Insulet had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $120.00. They now have a “neutral” rating on the stock.
  • 6/18/2019 – Insulet was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.

Shares of Insulet stock traded up $4.23 during midday trading on Thursday, hitting $150.62. 18,332 shares of the company traded hands, compared to its average volume of 593,294. The stock has a market capitalization of $9.10 billion, a PE ratio of 3,012.40 and a beta of 1.08. The company has a debt-to-equity ratio of 2.43, a quick ratio of 3.91 and a current ratio of 4.72. The business has a fifty day simple moving average of $125.91. Insulet Co. has a 12 month low of $70.80 and a 12 month high of $155.52.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $177.10 million for the quarter, compared to the consensus estimate of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. The company’s revenue for the quarter was up 42.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.03) earnings per share. As a group, equities research analysts predict that Insulet Co. will post 0.26 earnings per share for the current year.



In other Insulet news, insider Shacey Petrovic sold 895 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $113.00, for a total transaction of $101,135.00. Following the sale, the insider now directly owns 95,559 shares of the company’s stock, valued at approximately $10,798,167. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sally Crawford sold 28,347 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $108.60, for a total transaction of $3,078,484.20. Following the sale, the director now directly owns 28,469 shares in the company, valued at $3,091,733.40. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace North America L.P. bought a new stake in shares of Insulet in the 2nd quarter valued at $87,481,000. Nuveen Asset Management LLC boosted its stake in shares of Insulet by 1,731.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 355,561 shares of the medical instruments supplier’s stock valued at $42,447,000 after purchasing an additional 336,148 shares during the last quarter. William Blair Investment Management LLC boosted its stake in shares of Insulet by 15.7% in the 1st quarter. William Blair Investment Management LLC now owns 2,144,988 shares of the medical instruments supplier’s stock valued at $203,967,000 after purchasing an additional 290,790 shares during the last quarter. Rock Springs Capital Management LP bought a new stake in shares of Insulet in the 2nd quarter valued at $29,188,000. Finally, Frontier Capital Management Co. LLC boosted its stake in shares of Insulet by 12.3% in the 1st quarter. Frontier Capital Management Co. LLC now owns 1,958,736 shares of the medical instruments supplier’s stock valued at $186,256,000 after purchasing an additional 214,033 shares during the last quarter.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Featured Article: Trading Ex-Dividend Strategy

Receive News & Ratings for Insulet Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co and related companies with MarketBeat.com's FREE daily email newsletter.